Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (high certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) showed no clear difference in heart failure hospitalisation (RR) compared with placebo or no treatment (high certainty).
1 finding from 1 review
Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) leads to higher hyperkalaemia compared with placebo or no treatment (high certainty).
1 finding from 1 review
All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (high certainty).
1 finding from 1 review
Quality of life (MLHFQ): from 0 to 105 · patients with chronic heart failure with preserved ejection fraction
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in cardiovascular mortality (RR) Median compared with usual care (moderate certainty).
1 finding from 1 review
Time to first hospitalisation for heart failure during · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in heart failure hospitalisation, first (RR) Range of compared with usual care (moderate certainty).
1 finding from 1 review
Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in hyperkalaemia Range of compared with usual care (moderate certainty).
1 finding from 1 review
All‐cause mortality (RR) Range of · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor neprilysin inhibitors (ARNIs) leads to lower all‐cause mortality (RR) Range of compared with usual care (high certainty).
1 finding from 1 review
Quality of life Range of · patients with chronic heart failure with preserved ejection fraction
1 finding from 1 review
no estimate extracted
118 participants
High
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction
Mineralocorticoid receptor antagonists (MRAs) probably leads to lower heart failure hospitalisation (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction
Mineralocorticoid receptor antagonists (MRAs) leads to higher hyperkalaemia compared with placebo or no treatment (high certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic heart failure with preserved ejection fraction
Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in all‐cause mortality compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality (within 30 days) · adults undergoing cardiac surgery under general anaesthesia
The intervention showed no clear difference in all‐cause mortality (within 30 days) (low certainty).
1 finding from 1 review
Intervention not reported
Acute myocardial infarction (within 30 days) · adults undergoing cardiac surgery under general anaesthesia
The intervention showed no clear difference in acute myocardial infarction (within 30 days) (low certainty).
1 finding from 1 review
Intervention not reported
Cerebrovascular events (within 30 days) · adults undergoing cardiac surgery under general anaesthesia
It is very uncertain whether the intervention changes cerebrovascular events (within 30 days) (very low certainty).
1 finding from 1 review
Intervention not reported
Ventricular arrhythmias (within 30 days) · adults undergoing cardiac surgery under general anaesthesia
The intervention may leads to lower ventricular arrhythmias (within 30 days) (low certainty).
1 finding from 1 review
Intervention not reported
Atrial fibrillation or flutter, or both (within 30 days) · adults undergoing cardiac surgery under general anaesthesia
The intervention may leads to lower atrial fibrillation or flutter, or both (within 30 days) (low certainty).
1 finding from 1 review
Intervention not reported
Bradycardia (within 30 days; as defined by study authors, minimum heart rate < 60 beats per minute or requiring medication) · adults undergoing cardiac surgery under general anaesthesia
The intervention showed no clear difference in bradycardia (within 30 days; as defined by study authors, minimum… (low certainty).
1 finding from 1 review